Develops investigational drug treatments for people with endocrine conditions and neurodegenerative diseases, including post-bariatric hypoglycemia, Wolfram syndrome and ALS.
10-K for FY2025, filed Mar 3, 2026Amylyx Pharmaceuticals, Inc. (also referred to as Amylyx, we, our or us) is a clinical-stage pharmaceutical company with a mission to…View ↗
Our lead investigational asset is avexitide, a first-in-class glucagon-like peptide-1, or GLP-1, receptor antagonist. Avexitide has been…View ↗
In addition to avexitide, we are advancing AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol in Wolfram…View ↗
10-Q for Q3 FY2026, filed Nov 5, 2026
−$45.5MView ↗
Commercial sales ended
The earlier report described RELYVRIO and ALBRIOZA as marketed ALS treatments. The latest describes Amylyx as clinical-stage and says it discontinued those products and does not expect further sales revenue.
10-K for FY2022, filed Mar 13, 2023 10-K for FY2025, filed Mar 3, 2026Our mission is to one day end the suffering caused by neurodegenerative diseases. We are committed to supporting and creating more moments…View ↗
Amylyx Pharmaceuticals, Inc. (also referred to as Amylyx, we, our or us) is a clinical-stage pharmaceutical company with a mission to…View ↗
Revenue recognition—In June 2022, AMX0035 received marketing authorization with conditions as ALBRIOZA by Health Canada for the treatment…View ↗
3. PRODUCT REVENUE, NETView ↗
Broader disease focus
The earlier report centered on a marketed ALS treatment and neurodegenerative diseases; the latest also describes endocrine programs for post-bariatric hypoglycemia and Wolfram syndrome.
10-K for FY2022, filed Mar 13, 2023 10-K for FY2025, filed Mar 3, 2026Amylyx Pharmaceuticals, Inc. (also referred to as Amylyx, we, our or us) is a clinical-stage pharmaceutical company with a mission to…View ↗
Our lead investigational asset is avexitide, a first-in-class glucagon-like peptide-1, or GLP-1, receptor antagonist. Avexitide has been…View ↗
In addition to avexitide, we are advancing AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol in Wolfram…View ↗
AMX0318 is a novel GLP-1 receptor antagonist for long-acting administration selected as a development candidate for PBH and other rare…View ↗
Loading...